Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
13481
-
13482
-
13483
-
13484
-
13485
-
13486
-
13487
-
13488
-
13489
-
13490
-
13491
-
13492
-
13493
-
13494
-
13495
-
13496
-
13497
-
13498
Table5_Evidence and Potential Mechanism of Action of Lithospermum erythrorhizon and Its Active Components for Psoriasis.docx
Published 2022“…All data were analyzed using RevMan 5.3 software. The Cochrane and SYRCLE’s risk-of-bias tools were used to assess the quality of all studies.…”
-
13499
Table5_Evidence and Potential Mechanism of Action of Lithospermum erythrorhizon and Its Active Components for Psoriasis.docx
Published 2022“…All data were analyzed using RevMan 5.3 software. The Cochrane and SYRCLE’s risk-of-bias tools were used to assess the quality of all studies.…”
-
13500
Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis
Published 2016“…Pooled analysis revealed significant improvements in FEV<sub>1</sub> (first second forced expiratory volume) (MD = 0.09, 95% CI: 0.06–0.12, <i>I</i><sup><i>2</i></sup> = 10%), FEV<sub>1</sub>% (MD = 3.75, 95% CI: 1.66–5.83, <i>I</i><sup><i>2</i></sup> = 19%), Asthma Quality of Life Questionnaire (AQLQ) score (MD = 0.22, 95% CI: 0.15–0.30, <i>I</i><sup><i>2</i></sup> = 0%), decreased blood, sputum eosinophils and asthmatic exacerbation (RR = 0.66, 95% CI: 0.59–0.73, <i>I</i><sup><i>2</i></sup> = 51%); peak expiratory flow (PEF) (MD = 5.45, 95% CI: -2.83–13.72, <i>I</i><sup><i>2</i></sup> = 0%), histamine PC<sub>20</sub> (MD = -0.62, 95% CI: -1.92–0.68, <i>I</i><sup><i>2</i></sup> = 0%) or SABA rescue use (MD = -0.11, 95% CI: -0.3–0.07, <i>I</i><sup><i>2</i></sup> = 30%) were unaffected; adverse events were not increased (RR = 0.93, 95% CI: 0.89–0.98, <i>I</i><sup><i>2</i></sup> = 46%). …”